Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer

Table 3 Survival analysis of the enrolled patients

Variables	Univariate analysis		Multivariate analysis
	HR value (95%CI)	P value	HR value	P value
Sex (male vs female)	0.893 (0.606-1.316)	0.893
Age (≤ 60 vs > 60 years)	0.956 (0.657-1.391)	0.814
Location of tumor (lower 1/3 vs middle 1/3 vs upper 1/3)	1.077 (0.866-1.339)	0.505
Degree of differentiation (well/moderate vs poor)	1.460 (0.992-2.147)	0.055
Amount of ascites (small vs moderate vs massive)	1.396 (1.108-1.758)	0.005	1.263 (1.027-2.240)	0.061
Peritoneal metastases	0.604 (0.379-0.961)	0.033	0.611 (0.374-0.997)	0.042
(Oligo vs multiple)
Treatment methods (control group vs RH-endostatin group)	1.516 (1.045-2.198)	0.028	1.516 (1.027-2.240)	0.036

RH-endostatin: Recombinant human endostatin.